Hematopoietic Stem Cell Transplantation: High Risk Diffuse Large Cell Lymphoma: Ginna G. Laport, MD Associate Professor of Medicine Division of Blood &

Slides:



Advertisements
Similar presentations
An Intergroup Randomised Trial of Rituximab versus a Watch & Wait Approach in Patients with Advanced Stage, Asymptomatic, Non-bulky Follicular Lymphoma.
Advertisements

Follicular Lymphoma Laurie H. Sehn, MDCM, MPH BC Cancer Agency Vancouver, Canada.
Follicular lymphoma Optimal primary therapy and consolidation ? Seminars in Hematological Oncology * Israel, April M. Dreyling, Dept. of Medicine.
Brentuximab Vedotin Should be the Second Line Regimen of Choice for Recurrent Hodgkin Lymphoma Prior to Stem Cell Transplant Catherine Diefenbach, MD Assistant.
Wilson WH et al. Proc ASH 2012;Abstract 686.
Supervisor: Vs 楊慕華醫師 Presenter: CR 周益聖醫師 N Engl J Med 2012;367:
Casulo C et al. Proc ASH 2013;Abstract 510.
CORAL: COllaborative trial in Relapsed Aggressive Lymphoma R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed.
MYC-associated and Double Hit Lymphomas
Current Uses and Outcomes of Hematopoietic Stem Cell Transplantation 2011 Summary Slides Worldwide SUM-WW11_1.ppt.
Jonathan W. Friedberg M.D., M.M.Sc. University of Rochester Medical Center Optimal frontline therapy for Follicular lymphoma: Do we need to start with.
Non-Hodgkin’s lymphomas-definition and epidemiology
Rituximab Maintenance: Stage III/IV Follicular Lymphoma (ECOG/CALGB E1496) Subset: 237 FL pts CVP x 6-8 → PR/CR (cyclophosphamide, vincristine, prednisone)
Eastern cooperative oncology group E1496: ECOG and CALGB Cyclophosphamide/Fludarabine (CF) with or without Maintenance Rituximab (MR) in Advanced Indolent.
Neue Perspektiven in der Therapie Follikulärer Lymphome.
A Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory CD30-Positive Non-Hodgkin Lymphomas: Interim Results in Patients with DLBCL.
Treatment with Bendamustine- Bortezomib-Dexamethasone in Relapsed/Refractory Multiple Myeloma Shows Significant Activity and Is Well Tolerated Ludwig H.
Controversies in Transplant for Lymphoma
MANAGEMENT OF MANTLE CELL LYMPHOMA IN TUNISIA R BEN LAKHAL, L KAMMOUN, K ZAHRA, S KEFI Sousse 25 MAY 2012.
Background Diffuse large B-cell lymphoma (DLBCL) is the most commonly occurring lymphoma in the Western world. It’s account for about one-third of all.
Treatment of B Cell Malignancies: Current and Emerging Strategies Thomas A. Rado, MD, PhD.
NHL13: A Multicenter, Randomized Phase III Study of Rituximab as Maintenance Treatment versus Observation Alone in Patients with Aggressive B ‐ Cell Lymphoma.
Sequential Dose-Dense R-CHOP Followed by ICE Consolidation (MSKCC Protocol ) without Radiotherapy for Patients with Primary Mediastinal Large B Cell.
Alternating Courses of CHOP and DHAP Plus Rituximab (R) Followed by a High-Dose Cytarabine Regimen and ASCT is Superior to Six Courses of CHOP Plus R Followed.
Reduced-Intensity Conditioning (RIC) and Allogeneic Stem Cell Transplantation (allo-SCT) for Relapsed/Refractory Hodgkin Lymphoma (HL) in the Brentuximab.
Rituximab maintenance for the treatment of indolent NHL Dr Christian Buske.
Bortezomib Induction and Maintenance Treatment Improves Survival in Patients with Newly Diagnosed Multiple Myeloma: Extended Follow-Up of the HOVON-65/GMMG-HD4.
Optimizing Timing of Transplant in Hodgkin Lymphoma Ginna G. Laport, MD Associate Professor of Medicine Division of Blood & Marrow Transplantation Stanford.
Dose-Adjusted EPOCH plus Rituximab in Untreated Patients with Poor Prognosis Large B-Cell Lymphoma, with Analysis of Germinal Center and Activated B-Cell.
A phase III trial comparing R-CHOP 14 and R-CHOP 21 for the treatment of newly diagnosed diffuse large B cell lymphoma Results from a UK NCRI Lymphoma.
DLBCL with less than PR to second line therapy… Correcting a Misconception…. Koen van Besien, MD Weill Cornell Medical College, NY.
Rituximab Maintenance versus Wait and Watch After Four Courses of R-DHAP Followed by Autologous Stem Cell Transplantation in Previously Untreated Young.
Gray Zone Lymphoma (GZL) with Features Intermediate between Classical Hodgkin Lymphoma (cHL) and Diffuse Large B-Cell Lymphoma (DLBCL): A Large Retrospective.
Bachy and Salles. Seminars in Hematology, Vol 52, No 2, April 2015.
Optimal use of rituximab in aggressive NHL
What is the best approach for a follicular lymphoma patient who achieves CR after frontline chemoimmunotherapy? Radioimmunotherapy! Matthew Matasar,
Randomized Phase III US/Canadian Intergroup Trial (SWOG S9704) Comparing CHOP ± R for Eight Cycles to CHOP ± R for Six Cycles Followed by Autotransplant.
Future directions: Can we improve outcomes in relapsed/refractory DLBCL or aggressive NHL? Bertrand Coiffier Service d’Hématologie Hospices Civils de Lyon.
Significant Prognostic Impact of [18F]Fluorodeoxyglucose-PET Scan Performed During and at the End of Treatment with R-CHOP in High- Tumor Mass Follicular.
Lenalidomide Maintenance After Stem-Cell Transplantation for Multiple Myeloma: Follow-Up Analysis of the IFM Trial Attal M et al. Proc ASH 2013;Abstract.
Moskowitz CH et al. Proc ASH 2014;Abstract 673.
Phase II Trial of R-CHOP plus Bortezomib Induction Therapy Followed by Bortezomib Maintenance for Previously Untreated Mantle Cell Lymphoma: SWOG 0601.
R-CHOP with Iodine-131 Tositumomab Consolidation for Advanced Stage Diffuse Large B-Cell Lymphoma (DLBCL): Southwest Oncology Group Protocol S0433 Friedberg.
Brentuximab Vedotin in Combination with RCHOP as Front-Line Therapy in Patients with DLBCL: Interim Results from a Phase 2 Study Yasenchak CA et al. Proc.
ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic.
A European Collaborative Study of 230 Patients to Assess the Role of Cyclophosphamide, Bortezomib and Dexamethasone in Upfront Treatment of Patients with.
THE ROLE OF AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN THE TREATMENT OF NON-HODGKIN’S LYMPHOMA Christos Kosmas, M.D., Ph.D., Consultant Medical.
The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma.
Treatment of non-Hodgkin Lymphomas
Diffuse Large B-Cell Lymphoma: Current Standards of Care and Clinical Advances Christopher R. Flowers, MD, MS Director, Lymphoma Program Medical Director,
Non-Hodgkin Lymphoma March 13, 2013 Suzanne R. Fanning, DO Greenville Health System.
BENEFIT OF CONSOLIDATIVE RADIATION THERAPY IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH R-CHOP CHEMOTHERAPY JACK PHAN, ALI MAZLOOM, L. JEFFREY.
CCO Independent Conference Highlights
Non-Hodgkin’s Lymphoma
Vose JM et al. Proc ASH 2011;Abstract 661.
A Phase III Randomized Intergroup Trial (SWOG S0016) of CHOP Chemotherapy plus Rituximab vs CHOP Chemotherapy plus Iodine-131-Tositumomab for the Treatment.
Palumbo A et al. Proc ASH 2012;Abstract 200.
Maury S et al. Proc ASH 2015;Abstract 1.
Slide set on: McCarthy PL, Owzar K, Hofmeister CC, et al
CALGB/Alliance 50303: R-CHOP vs DA-EPOCH-R in Newly Diagnosed Diffuse Large B-Cell Lymphoma New Findings in Hematology: Independent Conference Coverage.
Fujiwara H et al. Proc ASH 2015;Abstract 181.
R-CHOP Stem Cell Transplantation for Follicular Lymphoma
Jonathan W. Friedberg M.D., M.M.Sc.
Jonathan W. Friedberg M.D., M.M.Sc.
ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION for MULTIPLE MYELOMA
What is the optimal management of an asymptomatic 62 year old with low tumor burden, stage IV, grade 1-2 FL? Answer: R-chemotherapy Peter Martin,
Stephen Ansell, MD, PhD Mayo Clinic
Anas Younes, M.D. Memorial Sloan Kettering Cancer Center
Presented by: Dr.Naser Shagerdi Esmaeli
Role for XRT in treatment of early stage Follicular lymphoma?
Presentation transcript:

Hematopoietic Stem Cell Transplantation: High Risk Diffuse Large Cell Lymphoma: Ginna G. Laport, MD Associate Professor of Medicine Division of Blood & Marrow Transplantation Stanford University Medical Center

Diffuse Large B-Cell Lymphoma: Stem Cell Transplantation for High Risk Patients Identifying “High Risk” Patients Autologous HSCT in High Risk Patients Phase II Trials Phase III Trials Allogeneic HCT

Transplants Transplant Activity Worldwide

Indications for Hematopoietic Stem Cell Transplants in the U.S. Number of Transplants

clinicaloptions.com/oncology Evolving Options and Challenges in Mantle Cell Lymphoma  Most common NHL: 31% –Peak incidence in 6th decade  Large cells with loss of follicular architecture of node –30% to 40% present with rapidly enlarging, symptomatic mass with B symptoms  Frontline chemotherapy (anthracycline-based + RTX) –CR  50-60% –Long term remission -> 30-35% Diffuse Large B-Cell Lymphoma

clinicaloptions.com/oncology Evolving Options and Challenges in Mantle Cell Lymphoma 5 Sehn LH, et al. Blood. 2007;109:1857 LegendRevised IPI Risk Group IPI Factors, n Very good0 Good1, 2 Poor3, 4, 5 Age >60 Perf Status Stage 3-4 LDH Extranodal Overall Survival According to Revised International Prognostic Index

clinicaloptions.com/oncology Evolving Options and Challenges in Mantle Cell Lymphoma Yrs OS Diffuse Large B-Cell Lymphoma DLBCL Subgroup5-Yr OS, % Primary Mediastinal64 Germinal Center B cell like (GCB) 59 Activated B cell (ABC) Rosenwald A, et al. J Exp Med. 2003;198: Survival by Gene Expression Profiling: DLBCL

Prognosis By Interim PET Scanning -Mixed results seen in 4 studies -2 studies confirm predictive value, 2 studies did not Safar et al, J Clin Oncol 2012;30: Time (months) PET positive (n=12) P=0.02 PET negative (n=73) Progression Free Survival n= Time (years) PET Positive P=0.146 PET Negative 24 Moskowicz et al. J Clin Oncol 2010;11: 1896 Progression Free Survival n= 112

High Risk Diffuse Large Cell Lymphoma Autologous HSCT in First CR/PR

High Risk Diffuse Large B Cell NHL: Frontline Autologous HCT Phase II Trials containing rituximab Groupn aaIPI >2 Therapy CR Rate PFS /EFS OS Follow up Tarella Mod R-HDS yrs Vitolo R-mega CEOP x BEAM/HCT yrs Dilhudy R CEEP BEAM HCT yrs Fitoussi R-ACVBP + BEAM/HCT yrs

Cochrane Database Sys Rev 2008;CD Meta-analysis: Autologous HSCT as Front Line Therapy N = 2228 No survival advantage for autologous HSCT in CR1 Haematologica 2003;88:1304 N = 3079 Overall survival advantage for autologous HSCT in CR1 compared to chemotherapy

clinicaloptions.com/oncology Evolving Options and Challenges in Mantle Cell Lymphoma Pts with ≥ PR after CHOP ± RTX x 5 (N = 253) CHOP ± Rituximab x 1 + Autologou HSCT* (n = 125) CHOP ± Rituximab x 3 (n = 128) Stiff PJ, et al. ASCO Abst R-CHOP x 8 vs R-CHOP x 6 Cycles + Autologous HSCT (SWOG S9704) Eligibility: Bulky stage 2-4 Hi-int/High IPI

clinicaloptions.com/oncology Evolving Options and Challenges in Mantle Cell Lymphoma Stiff PJ, et al. ASCO Abstr Outcome, %CHOP ± R + AutoSCT (n = 125) CHOP ± R (n = 128) P Value 2-yr PFS (all)69%56%.005  High-interm IPI 60%63 %  High IPI 75%47 %.02 2-yr OS (all)74%71%.16  High-inter IPI pts 70%75%  High IPI pts 82%64%.01  Autologous HSCT prolonged PFS  high-intermediate  high-IPI  Autologous HSCT prolonged OS  high-IPI ASCT After CHOP ± Rtx Improves PFS in Advanced High-Risk Diffuse NHL

clinicaloptions.com/oncology Evolving Options and Challenges in Mantle Cell Lymphoma Newly diagnosed DLBCL, aaIPI > 2 n = 399 Newly diagnosed DLBCL, aaIPI > 2 n = 399 RANDOMIZERANDOMIZE RANDOMIZERANDOMIZE R-CHOP x 3 R-mega CHOP SD, PD off study PR, CR Ann Oncol 2011; 22 suppl 4: abstr 72. RANDOMIZERANDOMIZE RANDOMIZERANDOMIZE BEAM  AutoHCT Observation only Italian Lymphoma Foundation 2 x 2 Randomized Trial with Autologous HSCT in High Risk Patients

Italian Lymphoma Foundation 2 x 2 Randomized Trial with Autologous HCT in High Risk Patients (median followup = 23 mos) PFSOS No BMT5983 BMT7283 P value.008NS - Risk of relapse was 53% lower in BMT patients - No overall survival difference between two arms` Months HDT No-HDT Progression Free Survival P=.008

High Risk Diffuse Large Cell Lymphoma Is there a role for allogeneic HSCT??

Years Survival after Allogeneic HCT for Diffuse Large B-Cell Lymphoma, By Disease Status Probability of Survival, % P < Sensitive (N=383) Resistant (N=124)

Reduced Intensity Allogeneic HSCT (after autologous HSCT relapse) nAblat/RICOSPFSNRMF/U EBMT10137%; 64%53%41%28%3 yrs Italian16530%; 70%39%32%28%2 yrs Factors affecting outcomes Dz status at time of allogeneic HCT Time to relapse after autologous HCT ( 12 m) Did not affect outcome Prep regimen Rigacci et al, Ann Heme 2012;91:931 van Kampen et al. JCO 2011;29:1342

Need better tools to identify high risk patients Current studies suggest that high-IPI subtype may benefit from autologous HCT early as front line therapy More studies needed to further define role of autologous HSCT as front line therapy –Need study that includes only ABC-subtype Role of allogeneic HSCT in high risk population? Hematopoietic SCT for High Risk DLBCL

Stanford University

clinicaloptions.com/oncology Evolving Options and Challenges in Mantle Cell Lymphoma Relapsed/ refractory DLBCL n = 396 Relapsed/ refractory DLBCL n = 396 RANDOMIZERANDOMIZE RANDOMIZERANDOMIZE R-ICE x 3 R-DHAP x 3 Auto SCT SD, PD off study PR, CR J Clin Oncol 2010; 28:4184–4190. Which salvage regimen is the best? RANDOMIZERANDOMIZE RANDOMIZERANDOMIZE Rituximab q2mos x 6 Rituximab q2mos x 6 Observation only Role of maintenance rituximab Role of maintenance rituximab CORAL Trial: Collaborative Trial in Relapsed Aggressive Lymphoma

clinicaloptions.com/oncology Evolving Options and Challenges in Mantle Cell Lymphoma Overall SurvivalEvent Free Survival P =.49 Mos P =.27 Mos R-ICE R-DHAP CORAL Trial Survival according to Salvage Regimen GCB vs ABC 3 yr PFS: 70% vs 28% R-DHAP vs R-ICE in GCB pts: 3 yr PFS: 100% vs 27%

CORAL Trial: EFS by relapse time after initial therapy Relapse > 12 mos from dxRelapse < 12 mos from dx predicted for poor outcome after autologous HCT

JCO 2012, In press EFS RTX Obs p=.74 PFS Female Male p=.04 Female pts benefited from RTX maintenance

CORAL: Factors affecting survival in relapsed DLCL patients EFSOS Prior rituximab Relapse < 12 mos<.0001 <.0001 sIPI<.0004<.0001 R-DHAP vs R-ICE (Except for GCB pts) p

clinicaloptions.com/oncology Evolving Options and Challenges in Mantle Cell Lymphoma Philip T, et al. N Engl J Med. 1995;333:1540 P = EFS (%) Mos After Randomization P = OS (%) Mos After Randomization Transplantation Conventional treatment PARMA Study: BMT vs Salvage Chemotx for Relapsed DLBCL Event Free SurvivalOverall Survival